Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BP 1002

Next Previous
Drug Profile

BP 1002

Alternative Names: BP-100-1.02; BP-1002; L-Bcl-2 antisense oligonucleotide; Liposomal Bcl-2; Liposomal Bcl-2 antisense

Latest Information Update: 13 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Bio-Path Holdings
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Gene silencing; Proto-oncogene protein c-bcl-2 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 11 Dec 2024 Bio-Path Holdings terminates a phase I trial in Lymphoma and Chronic Lymphocytic Leukemia (Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion) (NCT04072458)
  • 08 Jul 2024 Adverse events data from a phase I trial in Lymphoma and Chronic lymphocytic leukaemia released by Bio-Path Holdings
  • 15 Apr 2024 Bio-Path Holdings has patent protection for P-ethoxy nucleic acids for BCL2 inhibition in Australia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top